Envveno Medical CORP (NVNO) — Who's Buying and Selling (13F, Q2 2026)

NVNO ranks #8796 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

17 institutions disclose a position in NVNO, but none treat it as a major bet — even CM Management, LLC, its most concentrated holder, allocates just 0.2% of its own portfolio to it.

NVNO reported a net loss of $15.7M over the trailing twelve months.

• Not yet profitable — net loss of $15.7M over the trailing twelve months
• Revenue declined 83.3% year over year
• Net income improved year over year, from -$23.1M to -$15.7M
• Operating cash flow was negative, using $15.6M in cash
• Current ratio of 13.58x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range